Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 6 of 15 · 706 articles
Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
A nationwide clinician survey identifies major variation in how acute severe ulcerative colitis is diagnosed, monitored, and when rescue therapy or surgery is used — differences that can affect patient outcomes and...
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to...
Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Upadacitinib, and JAK inhibitor.
Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.
A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...
The trial explores a new way to boost regulatory T cells using low-dose IL-2, which could offer an alternative mechanism for people with Crohn's disease who haven't responded to existing therapies. It also links immune...
Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...
A successful Phase 3 trial could add guselkumab — an IL-23–targeting biologic — as a treatment option for people with moderate to severe Crohn's disease, especially those who haven’t responded to prior therapies.
The paper suggests that HRQoL and family functioning may be similar across disease types and common treatment approaches in children with IBD, but emotional health and parental worry remain areas needing attention.
This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...
This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
If successful, orally available small-molecule α4β7 inhibitors could offer a non-injectable alternative to current antibody therapy (vedolizumab) that targets the same gut-homing integrin—potentially widening treatment...
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
This large US claims study compares safety outcomes (serious infections, heart attacks/stroke, and venous clots) for tofacitinib versus multiple biologic therapies in people with ulcerative colitis — questions many...
An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...
This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...
Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to...
The study indicates that active inflammation—measured by CDAI and PDAI—drives poorer quality of life in Crohn's disease more than the mere presence of fistulas. That shifts focus toward controlling inflammation to...
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
NICE’s patient summary explains care expectations for people with Crohn’s disease, emphasising shared decision-making, symptom control, and understanding treatment options — practical points that affect everyday...
Patients with IBD may see TREMFYA appearing more widely as a treatment option and influencing which drugs companies prioritize. Rising sales and trial signals can speed access but don’t replace clinical guidance about...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis and Research and clinical trials. The original article is from Cochrane Database of Systematic...
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
Metformin is a common, inexpensive drug with possible anti-inflammatory effects; this review compiles preclinical and early clinical data suggesting it might influence ulcerative colitis biology. Readers may want to know...
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible...
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Early symptomatic improvement on filgotinib may predict longer-term gains in disease-specific quality-of-life for people with ulcerative colitis, which could help patients and clinicians set expectations during...
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
